Table 1 Study subject characteristics
From: Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies
Subject ID | Age | Sex | Drug | Biopsy diagnosis | LC3 (% positive fibers) | SQSTM1 (% positive fibers) | Keap1 (% positive fibers) |
|---|---|---|---|---|---|---|---|
Normal control group | |||||||
1 | 52 | F | None | Normal | 0.0 | 0.0 | 0.0 |
2 | 67 | F | None | Normal | 0.0 | 0.0 | 0.0 |
3 | 83 | F | None | Normal | 0.0 | 0.0 | 0.0 |
4 | 56 | F | None | Normal | 0.0 | 0.0 | 0.3 |
5 | 53 | M | None | Normal | 0.0 | 0.0 | 0.0 |
6 | 57 | M | None | Normal | 0.0 | 1.0 | 0.2 |
7 | 60 | M | None | Normal | 0.0 | 0.0 | 0.0 |
8 | 64 | F | None | Normal | 0.0 | 0.0 | ND |
9 | 48 | M | None | Normal | 0.0 | 0.0 | 0.0 |
10 | 32 | M | None | Normal | 0.0 | 0.0 | 0.0 |
Drug-treated control group | |||||||
11 | 32 | F | HCQ | Necrotizing myopathy | 13.0 | 10.5 | 4.5 |
12 | 58 | F | HCQ | Inflammatory myopathy | 2.5 | 4.3 | 2.0 |
13 | 33 | M | HCQ | Normal | 0.3 | 0.2 | 0.5 |
14 | 65 | F | HCQ | Neurogenic changes | 4.0 | 2.0 | 1.0 |
15 | 44 | F | Colchicine | Neurogenic changes | 1.8 | 1.5 | 1.0 |
16 | 47 | F | HCQ | Normal | 0.8 | 0.3 | 1.0 |
17a | 60 | F | HCQ | Polymyositis; neurogenic changes | 0.5 | 2.0 | 2.0 |
18a | 59 | F | HCQ | Normal | 4.3 | 2.3 | 3.8 |
19a | 31 | F | HCQ | Inflammatory myopathy | 0.8 | 0.5 | 2.0 |
Toxic autophagic vacuolar myopathy group | |||||||
20 | 73 | M | Colchicine | Toxic AVM | 64.0 | 86.0 | 72.0 |
21 | 58 | M | Colchicine | Toxic AVM | 22.5 | 14.8 | 8.0 |
22 | 81 | F | Colchicine | Toxic AVM | 78.0 | 83.5 | 87.0 |
23 | 84 | M | Colchicine | Toxic AVM | 58.5 | 65.0 | 60.0 |
24 | 80 | M | Colchicine | Toxic AVM | 13.0 | 21.0 | 34.0 |
25 | 72 | F | HCQ | Toxic AVM | 56.5 | 53.0 | 45.5 |
26 | 33 | F | HCQ | Toxic AVM | 18.0 | 12.5 | 13.5 |
27 | 79 | M | Colchicine | Toxic AVM | 79.0 | 79.5 | 49.0 |
28 | 79 | M | Colchicine | Toxic AVM | 95.0 | 93.0 | 78.0 |
29 | 29 | M | HCQ | Toxic AVM | 12.5 | 25.5 | 31.5 |
30a | 62 | F | Colchicine | Toxic AVM | 21.8 | 27.3 | 37.3 |
31a | 66 | M | Colchicine | Toxic AVM | 17.5 | 18.3 | 10.5 |
32a | 24 | F | HCQ | Toxic AVM | 10.5 | 12.5 | 14.0 |
Polymyositis group | |||||||
33 | 59 | M | None | Polymyositis | 5.7 | 5.5 | 5.0 |
34 | 85 | M | None | Polymyositis | 6.0 | 10.0 | 6.0 |
35 | 51 | F | None | Polymyositis | 4.0 | 0.3 | 0.5 |
36 | 65 | M | None | Polymyositis | 2.5 | 3.7 | 1.5 |
37 | 47 | M | None | Polymyositis | 1.7 | 11.0 | 9.0 |
38 | 42 | M | None | Polymyositis | 11.3 | 10.2 | 3.0 |
39 | 66 | F | None | Polymyositis | 3.8 | 4.0 | 0.5 |
40 | 59 | M | None | Polymyositis | 6.7 | 8.3 | 5.5 |
41 | 53 | M | None | Polymyositis | 2.7 | 19.2 | 12.5 |
42 | 43 | M | None | Polymyositis | 2.7 | 4.0 | 1.5 |
43 | 50 | M | None | Polymyositis | 2.0 | 2.8 | 0.5 |
Inclusion body myositis group | |||||||
44 | 64 | F | None | IBM | 31.0 | 18.5 | 24.0 |
45 | 57 | F | None | IBM | 24.0 | 20.0 | 34.0 |
46 | 62 | M | None | IBM | 29.5 | 59.5 | 48.5 |
47 | 77 | M | None | IBM | 15.5 | 16.5 | 15.5 |
48 | 74 | F | None | IBM | 16.0 | 9.0 | 7.0 |
49 | 73 | F | None | IBM | 34.0 | 32.0 | 24.0 |
50 | 69 | F | None | IBM | 48.5 | 43.5 | 20.5 |
51 | 75 | M | None | IBM | 11.0 | 22.5 | 20.0 |
52 | 59 | M | None | IBM | 33.5 | 36.0 | 40.0 |
53 | 66 | M | None | IBM | 9.0 | 15.0 | 6.5 |
54 | 76 | M | None | IBM | 32.5 | 12.0 | 27.5 |
55b | 80 | M | None | IBM | 9.5 | 13.5 | 11.8 |